- NOR-MS: Comparing treatment with cladribine and rituximab
- NEVROVAX: Study of responses to vaccination against influenza and COVID-19
- LEM-PASS: Safety follow-up after treatment with alemtuzumab (Sponsor Sanofi)
- CLAD-CROSS: A prospective study of safety and efficacy when switching to cladribine (Sponsor Merck)
- COMB157G23101: A prospective study of efficacy and safety when switching from dimethylfumarate or fingolimod to ofatumumab (Sponsor Novartis)
- GEMINI: Double blind, randomized study comparing BTKi-inhibitor with teriflunomide in RRMS (Sponsor Sanofi)
- HERCULES: Double blind, randomized study comparing BTKi-inhibitor with placebo in SPMS (Sponsor Sanofi)